Chang-Lu Hu

918 total citations · 1 hit paper
17 papers, 389 citations indexed

About

Chang-Lu Hu is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chang-Lu Hu has authored 17 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 8 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chang-Lu Hu's work include Esophageal Cancer Research and Treatment (6 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Chang-Lu Hu is often cited by papers focused on Esophageal Cancer Research and Treatment (6 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Chang-Lu Hu collaborates with scholars based in China, Ethiopia and United States. Chang-Lu Hu's co-authors include Hong Luo, Jiyan Liu, Benkang Shi, Xinan Sheng, Jianming Ying, Xin Yao, Jun Guo, Yanxia Shi, Zhisong He and Aiping Zhou and has published in prestigious journals such as Journal of Clinical Oncology, The Science of The Total Environment and Clinical Cancer Research.

In The Last Decade

Chang-Lu Hu

17 papers receiving 386 citations

Hit Papers

Open-label, Multicenter, Phase II Study of RC48-ADC, a HE... 2020 2026 2022 2024 2020 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
    2020 192 citations Xinan Sheng, Xieqiao Yan et al. Clinical Cancer Research profile →

Peers

Chang-Lu Hu
Zongbin Xu China
Spyros Triantos United States
Kristen K. Ciombor United States
Meiling Zhu China
Cristina Smolenschi France
Hiroki Fukunaga Japan
Ah-Rong Nam South Korea
Shumei Jiang China
Wichit Arpornwirat Thailand
Jean Philippe Metges France
Zongbin Xu China
Chang-Lu Hu
Citations per year, relative to Chang-Lu Hu Chang-Lu Hu (= 1×) peers Zongbin Xu

Countries citing papers authored by Chang-Lu Hu

Since Specialization
Citations

This map shows the geographic impact of Chang-Lu Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chang-Lu Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chang-Lu Hu more than expected).

Fields of papers citing papers by Chang-Lu Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chang-Lu Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chang-Lu Hu. The network helps show where Chang-Lu Hu may publish in the future.

Co-authorship network of co-authors of Chang-Lu Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Chang-Lu Hu. A scholar is included among the top collaborators of Chang-Lu Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chang-Lu Hu. Chang-Lu Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Hu, Chang-Lu, Xue Zhang, Jing Li, et al.. (2023). Black carbon derived from pyrolysis of maize straw and polystyrene microplastics affects soil biodiversity. The Science of The Total Environment. 881. 163398–163398. 7 indexed citations
3.
4.
Qin, Hanlin, et al.. (2022). The efficient circulating immunoscore predicts prognosis of patients with advanced gastrointestinal cancer. World Journal of Surgical Oncology. 20(1). 233–233. 3 indexed citations
5.
Chen, Lijun, Hong Luo, Hailong Hu, et al.. (2022). MRG002-006: A multicenter phase II clinical trial of MRG002-ADC for unresectable locally advanced or metastatic urothelial cancer.. Journal of Clinical Oncology. 40(16_suppl). 4570–4570. 7 indexed citations
6.
Liu, Baogang, Dongqing Lv, Ying Cheng, et al.. (2022). Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced tumors.. Journal of Clinical Oncology. 40(16_suppl). 2512–2512. 7 indexed citations
7.
Sheng, Xinan, Zhisong He, Yanxia Shi, et al.. (2022). RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.. Journal of Clinical Oncology. 40(16_suppl). 4520–4520. 24 indexed citations
8.
Shi, Yuankai, Jianhua Chen, Helong Zhang, et al.. (2022). A phase II trial of ALK/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in ALK-positive and crizotinib-resistant advanced non–small cell lung cancer.. Journal of Clinical Oncology. 40(16_suppl). 9073–9073. 1 indexed citations
9.
Cui, Yayun, Yifu He, Chang-Lu Hu, et al.. (2022). Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial. Frontiers in Pharmacology. 13. 7 indexed citations
10.
Tang, Yan, et al.. (2021). High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma. Journal of Gastrointestinal Oncology. 12(1). 174–183. 21 indexed citations
11.
Sheng, Xinan, Zhisong He, Weiqing Han, et al.. (2021). An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).. Journal of Clinical Oncology. 39(15_suppl). 4584–4584. 25 indexed citations
12.
Chen, Qi, et al.. (2020). LncRNA MCM3AP-AS1 promotes breast cancer progression via modulating miR-28-5p/CENPF axis. Biomedicine & Pharmacotherapy. 128. 110289–110289. 45 indexed citations
13.
Sheng, Xinan, Xieqiao Yan, Lin Wang, et al.. (2020). Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 27(1). 43–51. 192 indexed citations breakdown →
14.
Hu, Chang-Lu, et al.. (2014). A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer. Anti-Cancer Drugs. 26(1). 101–105. 7 indexed citations
15.
16.
Chen, Jian, et al.. (2009). Intraperitoneal injection of recombinant human endostatin combined with fluorouracil on advanced cancers with malignant ascites.. Chinese Clinical Oncology. 14(3). 252–255. 2 indexed citations
17.
He, Yifu, et al.. (2007). Fatal lactic acidosis and hypoglycemia in a patient with relapsed natural killer/T-cell lymphoma. Advances in Therapy. 24(3). 505–509. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zongbin Xu Breakdown of academic impact, for papers by Spyros Triantos Breakdown of academic impact, for papers by Kristen K. Ciombor Breakdown of academic impact, for papers by Meiling Zhu Breakdown of academic impact, for papers by Cristina Smolenschi Breakdown of academic impact, for papers by Hiroki Fukunaga Breakdown of academic impact, for papers by Ah-Rong Nam Breakdown of academic impact, for papers by Shumei Jiang Breakdown of academic impact, for papers by Wichit Arpornwirat Breakdown of academic impact, for papers by Jean Philippe Metges
Rankless by CCL
2026